Dry ice

Global Dry Ice Market Forecast to 2028 - Players Include Continental Carbonic Products, Sicgil India, Linde and Dry Ice UK Among Others - ResearchAndMarkets.com

Retrieved on: 
Tuesday, October 25, 2022
Other Manufacturing, Manufacturing, Health, Transport, Growth, Vaccine, CAGR, CNN International Europe/Middle East/Africa, Carbon, Geography, MEA, Temperature, Industry, Food, Foodservice, Fermentation, Vaccination, Dry ice, COVID-19, Ice, Food preservation

The "Dry Ice Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Type and Application" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Dry Ice Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Type and Application" report has been added to ResearchAndMarkets.com's offering.
  • Dry ice can be created in a pelletizer or a block press, which makes them into pellets or large blocks.
  • Based on application, the dry ice market is segmented into food & beverage, storage & transportation, healthcare, industrial applications, and others.
  • Dry ice is also being increasingly used for transporting COVID-19 vaccines across the world, which is having a positive impact on the growth of the dry ice market.

CS Analytical Offers Comprehensive cGMP Cold Product Package System Qualification Program

Retrieved on: 
Wednesday, October 19, 2022
CCI, CGMP, EP, Dry ice, Area studies, FDA, Program, Glass, Elastomer, False vacuum decay, Cold, JP, Technology, Temperature, USP, Medical device

CLIFTON, N.J., Oct. 19, 2022 /PRNewswire-PRWeb/ -- CS Analytical Laboratory, the world's only cGMP, FDA-regulated contract laboratory exclusively designed and dedicated to container and package testing and regulatory solutions for the pharmaceutical, biotechnology, and medical device industries, is pleased to introduce a new comprehensive service offering designed specifically for the qualification of product-package systems requiring cold storage at or below -60°C. This program, based on a holistic science-based approach according to industry best practices, is scalable to cover all stages of the product lifecycle. Services built into these comprehensive programs include:

Key Points: 
  • "We are very excited to offer this type of program within our FDA regulated, cGMP facility," noted Brandon Zurawlow, Chief Scientific Officer.
  • "Having the ability to design and implement a comprehensive qualification program for cold storage package systems that spans the full product lifecycle, from development to commercialization, is a prime example of what we strive to deliver at CS Analytical.
  • The team at CS Analytical has leveraged its years of experience designing and implementing comprehensive qualification programs in addressing the market need of these new class of drugs requiring cold storage.
  • CS Analytical is the one source that can ensure your medical product container and package system meets the strict and complex regulatory requirements.

Orthofix and MTF Biologics Recognized with 2022 Spine Technology Award for Virtuos Lyograft – a First-of-Its-Kind, Shelf-Stable and Complete Autograft Substitute for Spine and Orthopedic Procedures

Retrieved on: 
Wednesday, October 12, 2022
Biotechnology, Physical Therapy, Publishing, Surgery, General Health, Health, Medical Devices, Communications, Insurance, Elective surgery, Drug Quality and Security Act, Communication, Risk, SEC, Technology, Efficiency, Science, Organization, Â, NASDAQ, Annual report, Cell, Patient, Hospital, Carbon, Deutsches Institut für Bautechnik, NASS, Multimedia, Securities Act of 1933, Temperature, North American Spine Society, Publication, Company, International Institute of Refrigeration, Advanced Therapy Medicinal Product, German Institute for Medical Documentation and Information, Securities Exchange Act of 1934, Overalls, Dry ice, Terminology, MTF, Surgeon, Bookbinding, Pharmaceutical industry, Dentistry, Medical device, Orthopedic surgery, Spine, Virtuos

View the full release here: https://www.businesswire.com/news/home/20221012005256/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20221012005256/en/
    Virtuos Lyograft is a first-of-its-kind, shelf-stable and complete autograft substitute for use with spine and orthopedic procedures (Photo: Business Wire)
    The Virtuos Lyograft is a first-of-its-kind, shelf-stable and complete autograft substitute prepared by MTF Biologics through a proprietary process that preserves the biological components necessary for bone healing.
  • Additionally, Virtuos offers significant logistical and cost-saving advantages to the hospital with improved shipping, storage and operating room efficiency.
  • We are pleased to present Orthofix and MTF Biologics with the Best Technology in Spine award for the Virtuos Lyograft.
  • On behalf of our partner MTF Biologics and the team of dedicated employees at Orthofix, we are honored to receive this award, said Orthofix President of Global Spine Kevin Kenny.

Shipt's Shoppable Halloween Trend Report Brings the Magic to the Season's Most Popular Costumes, Candy and Decor

Retrieved on: 
Tuesday, October 11, 2022
Newsroom, Chocolate, City, Life, M&M, Tree, Twitter, Multimedia, Candy, Television, Dry ice, Magic, Retail, Fireworks, Online shopping, Instagram, Facebook, Shipt

BIRMINGHAM, Ala., Oct. 11, 2022 /PRNewswire/ -- Shipt, the same-day delivery company and shopping accomplice is helping consumers navigate the magical Halloween season. With Halloween spending expected to spike to over $10.6 billion this year1, the go-to shopping accomplice is releasing the first-ever Shipt Halloween Trend Report – a shoppable list of costumes, candies and decor to bring the magic this Halloween season.

Key Points: 
  • With Halloween spending expected to spike to over $10.6 billion this year1, the go-to shopping accomplice is releasing the first-ever Shipt Halloween Trend Report a shoppable list of costumes, candies and decor to bring the magic this Halloween season.
  • "Our Halloween Trend Report not only taps into this year's most popular Halloween must-haves, but also helps consumers navigate the busy retail season and save money."
  • And the winner is M&M'S: According to Shipt's Halloween Trend Report, the most popular Halloween candy nationwide are M&M'S.
  • According to Shipt's Halloween Trend Report, the most popular decor theme you'll see this year is magic.

Dippin’ Dots Delivers Sweet Treats and an Engaging Customer Experience with BigCommerce

Retrieved on: 
Tuesday, October 4, 2022
Software, Internet, Data Management, Technology, Food, Beverage, Electronic Commerce, Online Retail, Retail, Dots, Chocolate, Software as a service, Food, LinkedIn, Nasdaq, CEO, Twitter, CSS, Instagram, Theo Chocolate, Ice cream, B2C, Animation, Dry ice, BIGC, Eye, Skullcandy, Love, Marketing, B2B, Online shopping, Facebook, BigCommerce, Vodafone

These enhancements to our website will allow customers to create new memories by bringing the Dippin Dots experience home for parties, gifts and more.

Key Points: 
  • These enhancements to our website will allow customers to create new memories by bringing the Dippin Dots experience home for parties, gifts and more.
  • With the addition of the new delivery date picker, customers plan ahead, selecting the perfect day for their Dippin Dots-inspired event.
  • We really wanted to create a magical experience for customers that reflects the Dippin Dots brand, said Ethan Griffin, CEO at Groove Commerce.
  • Dippin Dots is one of many food and beverage merchants leveraging the BigCommerce platform to drive sales and deliver a winning consumer experience.

Illumina Introduces Multiple Breakthrough Sequencing Innovations at Inaugural Genomics Forum

Retrieved on: 
Thursday, September 29, 2022
YouTube, Double-barrelled name, Francis deSouza, Health, RUO, Time, Agriculture, Gaps, Twitter, Illumina, Inc., FDA, LinkedIn, Compliance, Review, IVD, U.S. Securities and Exchange Commission, Ownership, Reproductive health, Technology, Instagram, Dry ice, NASDAQ, SAN, Genomics, Research, DNA, Security (finance), SBS, Infinity, Form 10-K, Genome, Patent, Disease, Fine chemical, Antibiotics, Illumina, Chemistry, Facebook

SAN DIEGO, Sept. 29, 2022 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced multiple breakthrough sequencing innovations at its inaugural Illumina Genomics Forum:

Key Points: 
  • Illumina Complete Long-Reads, formerly known as Infinity, will accelerate access to the remaining 5% of genic regions with a scalable, high-throughput, low DNA-input long read technology.
  • Further, the technology provides a complete and accurate representation of the genome at the single molecule level without needing a new platform.
  • These announcements came on the second day of the inaugural Illumina Genomics Forum, which runs through October 1.For more information, please visit illuminagenomicsforum.com .
  • Our focus on innovation has established us as a global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical and applied markets.

Illumina Unveils Revolutionary NovaSeq X Series to Rapidly Accelerate Genomic Discoveries and Improve Human Health

Retrieved on: 
Thursday, September 29, 2022
YouTube, Double-barrelled name, Software, Health, Therapy, Particle-size distribution, Time, Agriculture, Acceleration, Efficiency, Twitter, Illumina, Inc., Disease, ORA, LinkedIn, Population, Lists of diseases, Review, U.S. Securities and Exchange Commission, Patient, Genetics, Cancer, Reproductive health, CEO, Technology, Instagram, WGS, Dry ice, Doctor of Philosophy, Genetic distance, NASDAQ, Genomics, SAN, Heart, Data compression, Research, DNA, Security (finance), SBS, Form 10-K, Broad Institute, Genome, Chemistry, Antibiotics, Recycling, Medical imaging, Computer data storage, Illumina, Facebook, Macrogen

SAN DIEGO, Sept. 29, 2022 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced the launch of the NovaSeq™ X Series (NovaSeq X and NovaSeq X Plus), new production-scale sequencers that will push the limits of what is possible with genomic medicine, enabling faster, more powerful, and more sustainable sequencing. Using revolutionary new technology, NovaSeq X Plus can generate more than 20,000 whole genomes per year – 2.5 times the throughput of prior sequencers – greatly accelerating genomic discovery and clinical insights, to understand disease and ultimately transform patient lives.

Key Points: 
  • With its NovaSeq X Series, Illumina redesigned every dimension of its world-class sequencers to further increase speed, scale, accuracy, and sustainability.
  • NovaSeq X also significantly reduces waste and environmental impact, reflecting Illumina's commitment to using its technology to support the health of people and the planet.
  • NovaSeq X features a 90% reduction in packaging waste and weight and 50% reduction in plastic usage compared to NovaSeq 6000.
  • "I strongly believe NovaSeq X Series will accelerate our path towards the $100 genome.

Illumina Unveils Revolutionary NovaSeq X Series to Rapidly Accelerate Genomic Discoveries and Improve Human Health

Retrieved on: 
Thursday, September 29, 2022
YouTube, Double-barrelled name, Software, Health, Therapy, Particle-size distribution, Time, Agriculture, Acceleration, Efficiency, Twitter, Illumina, Inc., Disease, ORA, LinkedIn, Population, Lists of diseases, Review, U.S. Securities and Exchange Commission, Patient, Genetics, Cancer, Reproductive health, CEO, Technology, Instagram, WGS, Dry ice, Doctor of Philosophy, Genetic distance, NASDAQ, Genomics, SAN, Heart, Data compression, Research, DNA, Security (finance), SBS, Form 10-K, Broad Institute, Genome, Chemistry, Antibiotics, Recycling, Medical imaging, Computer data storage, Illumina, Facebook, Macrogen

SAN DIEGO, Sept. 29, 2022 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced the launch of the NovaSeq™ X Series (NovaSeq X and NovaSeq X Plus), new production-scale sequencers that will push the limits of what is possible with genomic medicine, enabling faster, more powerful, and more sustainable sequencing. Using revolutionary new technology, NovaSeq X Plus can generate more than 20,000 whole genomes per year – 2.5 times the throughput of prior sequencers – greatly accelerating genomic discovery and clinical insights, to understand disease and ultimately transform patient lives.

Key Points: 
  • With its NovaSeq X Series, Illumina redesigned every dimension of its world-class sequencers to further increase speed, scale, accuracy, and sustainability.
  • NovaSeq X also significantly reduces waste and environmental impact, reflecting Illumina's commitment to using its technology to support the health of people and the planet.
  • NovaSeq X features a 90% reduction in packaging waste and weight and 50% reduction in plastic usage compared to NovaSeq 6000.
  • "I strongly believe NovaSeq X Series will accelerate our path towards the $100 genome.

Tive Announces a Validated, Complete Cold Chain Solution for the Pharmaceutical & Biologicals Industries

Retrieved on: 
Thursday, September 29, 2022
Software, Temperature, GxP, ISO 17025, NIST, FDA, SOC, Technology, Title 21 CFR Part 11, Solution, Education in Hong Kong, Dry ice, Lithium, ISO, Good, Medical device, Calibration

BOSTON, Sept. 29, 2022 /PRNewswire/ -- Tive, the global leader in supply chain and logistics visibility technology, today announced a portfolio of real-time cold chain management logistics solutions for pharmaceutical, biologicals, and cell gene therapy companies. Tive's multi-sensor Solo 5G trackers capture and transmit hyper-accurate location and temperature data of shipments in real time—enabling customers to actively monitor in-transit shipments, take action when deviations occur, and identify areas for supply chain improvements.

Key Points: 
  • BOSTON, Sept. 29, 2022 /PRNewswire/ -- Tive , the global leader in supply chain and logistics visibility technology, today announced a portfolio of real-time cold chain management logistics solutions for pharmaceutical, biologicals, and cell gene therapy companies.
  • With this announcement, Tive now covers the full range of temperatures required to protect all critical cold chain shipmentsincluding dry ice and cryogenic shipments.
  • "Tive dedicated a tremendous amount of energy to create hardware and software offerings that give biotech, pharmaceutical, and cell gene therapy companies a complete cold chain solutionas well as a tremendous competitive advantage," says Krenar Komoni, Tive CEO & Founder.
  • In addition, the Tive cloud-based application complies with both FDA 21 CFR Part 11 and EU Annex 11 requirements.

Cold Jet Expands Global Footprint with Acquisition of Aquila Triventek's Dry Ice Product Line

Retrieved on: 
Thursday, September 22, 2022
CO2, Carbon, Efficiency, Senior, Acquisition, Industry, Letter, CEO, Technology, Dry ice, A/S, Marketing, Multimedia, View, Dry cleaning, Airline, Funen

LOVELAND, Ohio, Sept. 22, 2022 /PRNewswire/ -- Cold Jet, the global leader in dry ice technology, has signed a letter of intent to acquire Aquila Triventek's dry ice activities, a Danish company that specializes in developing innovative dry ice cleaning, production and CO2 recovery systems.

Key Points: 
  • LOVELAND, Ohio, Sept. 22, 2022 /PRNewswire/ -- Cold Jet, the global leader in dry ice technology, has signed a letter of intent to acquire Aquila Triventek's dry ice activities, a Danish company that specializes in developing innovative dry ice cleaning, production and CO2 recovery systems.
  • "This acquisition, at its core, will integrate dry ice technologies, innovations and staff from Triventek with the Cold Jet family and product portfolio," said Eugene Cooke, President & CEO of Cold Jet.
  • The CO2 recovery units pair perfectly with Cold Jet dry ice production systems , helping customers achieve even greater efficiencies with their dry ice operations.
  • "Triventek's advanced CO2 recovery systems made this opportunity especially unique in our effort to build a more sustainable carbon footprint for dry ice production," said Dennis Hjort, Senior Vice President Global DIMS & IBSof Cold Jet.